Leerink Partnrs Has Pessimistic View of SPRY FY2028 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2028 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research note issued to investors on Thursday, March 20th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings of $1.57 per share for the year, down from their previous forecast of $1.70. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.56. The firm had revenue of $86.58 million for the quarter, compared to analysts' expectations of $15.46 million.

A number of other analysts also recently commented on the company. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partners raised their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Scotiabank began coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price target on the stock. Raymond James raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. Finally, Oppenheimer started coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an "outperform" rating and a $40.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $31.00.

ARS Pharmaceuticals Stock Up 0.2 %

SPRY stock traded up $0.03 during trading on Monday, reaching $12.63. The stock had a trading volume of 1,549,755 shares, compared to its average volume of 1,067,730. ARS Pharmaceuticals has a one year low of $7.55 and a one year high of $18.51. The company's 50 day moving average is $12.14 and its two-hundred day moving average is $13.07. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -24.76 and a beta of 1.03.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Wellington Management Group LLP boosted its holdings in ARS Pharmaceuticals by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock valued at $1,722,000 after acquiring an additional 917 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of ARS Pharmaceuticals by 4.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 60,294 shares of the company's stock valued at $636,000 after purchasing an additional 2,670 shares during the period. Bernard Wealth Management Corp. purchased a new stake in shares of ARS Pharmaceuticals during the fourth quarter valued at approximately $27,000. Ball & Co Wealth Management Inc. bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth approximately $105,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of ARS Pharmaceuticals by 5.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 247,314 shares of the company's stock worth $2,609,000 after buying an additional 12,777 shares during the period. Hedge funds and other institutional investors own 68.16% of the company's stock.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the transaction, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Karas sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider now owns 7,696 shares of the company's stock, valued at approximately $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 159,600 shares of company stock valued at $1,866,516. Corporate insiders own 40.10% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.